The judges’ decision allows exceptions that may permit scientists’ travel from the blocked countries.

David Schwartz of the Illinois Institute of Technology-Chicago, Kent College of Law, discusses the impact of the US Supreme Court unanimously striking down Myriad Genetics' patent of human BRCA genes and tests to detect mutations in them.

How the US government impacted life science research in 2013

Overstating the benefits of a drug lands a former biotech executive in home detention.

August 2013's selection of notable quotes

Myriad Genetics, the company originally behind tests for the cancer-associated BRCA mutations, is suing two competitors for patent infringement.

July 2013's selection of notable quotes

Last week’s Supreme Court decision to invalidate patents on human genes was a win for patients, independent researchers, and even the wider biotech industry.

The scientific community and the impact of the Myriad Genetics Supreme Court decision